上海橙帆医药

Orange Sail Pharma is a Shanghai-based biotechnology company specializing in the development of next-generation RNA-based therapeutics. Founded in 2021 by Dr. Li Chen, the former head of the Roche Innovation Center Shanghai, the company leverages deep expertise in oligonucleotide chemistry and delivery. The firm's core technology centers on a proprietary GalNAc-siRNA delivery platform designed to enhance the stability and tissue-specific uptake of RNA medicines. Their pipeline primarily targets chronic conditions, including cardiovascular, metabolic, and liver-related diseases, with a focus on high-prevalence indications. Orange Sail has attracted significant investment from leading venture capital firms like Matrix Partners China and Qiming Venture Partners to accelerate its R&D efforts. The company aims to transform the treatment landscape for chronic diseases by providing potent, long-acting siRNA therapies that improve patient compliance and outcomes.